Ivana Pariggiano

Dr. Ivana Pariggiano

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Archives of Cardiovascular Diseases
Verified
Journal Article
Closed access
Paolo CalabròPaolo Calabrò
Paolo Calabrò
Felice GragnanoFelice Gragnano
Felice Gragnano
ACArturo Cesaro
Arturo Cesaro
FMFabio Marsico
Fabio Marsico
IPIvana Pariggiano
Ivana Pariggiano
Raffaele De CaterinaRaffaele De Caterina
Raffaele De Caterina

8 May 2017 in Angiology
Verified
Journal Article
Closed access
Felice GragnanoFelice Gragnano
Felice Gragnano
MCMario Crisci
Mario Crisci
MBMaurizio Cappelli Bigazzi
Maurizio Cappelli Bigazzi
RBRenatomaria Bianchi
Renatomaria Bianchi
Simona SperlonganoSimona Sperlongano
Simona Sperlongano
Paolo CalabròPaolo Calabrò
Paolo Calabrò
Von Willebrand Factor (vWF) is a well-known mediator of hemostasis and vascular inflammation. Its dynamic modulation in the bloodstream, according to hemodynamic conditions, makes it an appealing biomarker in patients with valvular heart disease (VHD). Recent studies highlight the close connection between vWF and VHD, with possible implications in the pathogenesis of VHD, promoting valve aging and calcification or favoring the development of infective endocarditis. Moreover, vWF has been recently proposed as a new diagnostic and prognostic tool in patients with valve stenosis or regurgitation, showing a strict correlation with severity of valve disease, outcome, and bleeding (Heyde syndrome). A novel role for vWF is also emerging in patients undergoing percutaneous or surgical valve repair/replacement to select and stratify patients, evaluate periprocedural bleeding risk, and detect procedural complications. We also report our single-center experience, suggesting, for the first time, possible clinical implications for vWF in percutaneous mitral valve repair (MitraClip). This review summarizes recent advances in the role of vWF in VHD with an updated overview going from bench to operating room.

31 July 2025 in Cardiogenetics
Verified
Journal Article
Open access
PDF file
MMMaria Chiara Meucci
Maria Chiara Meucci
RLRosa Lilo
Rosa Lilo
MCMargherita Maria Calcagnino
Margherita Maria Calcagnino
GTGiampaolo Tocci
Giampaolo Tocci
EAEustachio Agricola
Eustachio Agricola
FBFrancesco Bianchini
Francesco Bianchini
Background: Cardiac involvement is common in Fabry disease (FD) and typically manifests with left ventricular hypertrophy (LVH). Patients with FD are frequently misdiagnosed, and this is mainly related to the lack of disease awareness among clinicians. The aim of this study was to determine whether providing a targeted educational intervention on FD may enhance FD diagnosis. Methods. This research was designed as a single-arm before-and-after intervention study and evaluated the impact of providing a specific training on FD to cardiologists from different Italian centers, without experience in rare diseases. In the 12-month period after the educational intervention, the rate of FD screening and diagnosis was assessed and compared with those conducted in the two years preceding the study initiation. Results: Fifteen cardiologists participated to this study, receiving a theoretical and practical training on FD. In the two previous two years, they conducted 12 FD screening (6/year), and they did not detect any cases of FD. After the training, they performed 45 FD screenings, with an eight-fold rise in the annual screening rate. The screened population (age: 61 ± 11 years, men: 82%) was mainly composed of patients with unexplained LVH (n = 43). There were four new FD diagnoses and, among of them, three had a late-onset GLA variant. After the cascade genetic screening, 11 affected relatives and 8 heterozygous carriers were also detected. Conclusions: A targeted educational intervention for cardiologists allowed the identification of four new families with FD. Enhancing FD awareness is helpful to reduce the diagnostic and therapeutic delay.